Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 maternal RSVpreF vaccine trial for prevention of RSV lower respiratory tract illness in infants
NL-OMON52627Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing RSVpreF with Placebo (2 arms). Primary endpoints: Efficacy against medically attended RSV-associated lower respiratory tract illness, Efficacy against severe medically attended RSV-associated lower respiratory tract illness and 2 more. Started Oct 2020; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON52627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52627.